Life Tech Inks Supply Deal with Novartis for Dynabeads | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies today said that it has signed an agreement to supply Novartis with its Dynabeads for use in immunotherapeutics being developed by the drug firm for cancer.

The agreement includes a license to Life Tech's intellectual property to perform the resulting therapy and it is exclusive for use in the field of chimeric antigen receptors for the treatment of cancer. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.